



**Date: 28<sup>th</sup> July, 2020**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: BOARD MEETING INTIMATION TO CONSIDER UNAUDITED FINANCIAL RESULTS AND INTERIM DIVIDEND**

Dear Sir/Madam,

**NOTICE IS HEREBY** given that a Meeting of the Board of Directors of Eris Lifesciences Limited (“the Company”) is scheduled to be held on Tuesday, 04<sup>th</sup> August, 2020 to, inter alia, to:

- Consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30<sup>th</sup> June, 2020.
- Consider and approve the proposal for payment of Interim Dividend on the equity shares of the Company for the Financial Year 2020-21.

Further, as informed by us vide letter dated 30<sup>th</sup> June, 2020, the trading window has been already closed from 1<sup>st</sup> July, 2020 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company’ for the purpose of Board Meeting.

Thanking You,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867